Literature DB >> 1714327

Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.

R Repp1, T Valerius, A Sendler, M Gramatzki, H Iro, J R Kalden, E Platzer.   

Abstract

Fc receptors are important effector molecules of neutrophilic granulocytes (polymorphonuclear neutrophils [PMN]), connecting phagocytic cells and the specific immune response. Neutrophils from healthy donors express the low-affinity receptors for IgG Fc gamma RII (CD32) and Fc gamma RIII (CD16), but not the high-affinity receptor Fc gamma RI (CD64). The latter has been found on neutrophils from patients with certain bacterial infections and can be induced in vitro after incubation with interferon-gamma. We show here that neutrophils strongly express Fc gamma RI after in vivo application of recombinant human granulocyte colony-stimulating factor (rhG-CSF). PMN from patients receiving rhG-CSF displayed higher cytotoxicity against Daudi lymphoma cells in vitro compared with control patients and with healthy donors. Fab fragments against Fc gamma RII (monoclonal antibody [MoAb] IV.3) inhibited neutrophil-mediated cytotoxicity of healthy donors but not of patients during rhG-CSF therapy. Therefore, expression of Fc receptors by PMN was investigated by flow cytometry and the mean fluorescence intensity (MFI) was compared. After staining with MoAb 32.2 against Fc gamma RL, the median MFI of neutrophils from G-CSF patients (median, 4.78; range, 2.40 to 8.50; n = 5) was significantly higher (P = .002 and P = .001, respectively) than the median MFI of patients not receiving G-CSF (median, 1.23; range, 1.01 to 1.58; n = 6) and the median MFI of healthy donors (median, 1.04; range, 0.67 to 1.12; n = 6). Fc gamma RI disappeared after the discontinuing of the G-CSF injections, but was reinduced during the next treatment cycle with rhG-CSF. The high expression of Fc gamma RI during rhG-CSF therapy correlated with enhanced cytotoxicity. In vitro incubation with rhG-CSF also enhances cytotoxicity, but only minor increments in Fc gamma RI expression were observed. Thus, during in vivo application of rhG-CSF neutrophils acquire an additional potent receptor for mediating tumor cell killing in vitro by induction of the high-affinity receptor for IgG (Fc gamma RI, CD64).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714327

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Neutrophils from the synovial fluid of patients with rheumatoid arthritis express the high affinity immunoglobulin G receptor, Fc gamma RI (CD64): role of immune complexes and cytokines in induction of receptor expression.

Authors:  J A Quayle; F Watson; R C Bucknall; S W Edwards
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

2.  Maternal immunity provides protection against pertussis in newborn piglets.

Authors:  Shokrollah Elahi; Rachelle M Buchanan; Lorne A Babiuk; Volker Gerdts
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  G-CSF in Felty's syndrome: correction of neutropenia and effects on cytokine release.

Authors:  R Schots; L A Verbruggen; C Demanet
Journal:  Clin Rheumatol       Date:  1995-01       Impact factor: 2.980

4.  Felty's syndrome treated with rhG-CSF associated with flare of arthritis and skin rash.

Authors:  M F McMullin; M B Finch
Journal:  Clin Rheumatol       Date:  1995-03       Impact factor: 2.980

5.  Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.

Authors:  Niels Heemskerk; Mandy Gruijs; A Robin Temming; Marieke H Heineke; Dennis Y Gout; Tessa Hellingman; Cornelis W Tuk; Paula J Winter; Suzanne Lissenberg-Thunnissen; Arthur Eh Bentlage; Marco de Donatis; Marijn Bögels; Thies Rösner; Thomas Valerius; Jantine E Bakema; Gestur Vidarsson; Marjolein van Egmond
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

6.  C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity.

Authors:  Valerie R Wiersma; Marco de Bruyn; Ce Shi; Marloes J M Gooden; Maartje C A Wouters; Douwe F Samplonius; Djoke Hendriks; Hans W Nijman; Yunwei Wei; Jin Zhou; Wijnand Helfrich; Edwin Bremer
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  Flare of arthritis with successful treatment of Felty's syndrome with granulocyte colony stimulating factor (GCSF).

Authors:  S Q Hayat; M Hearth-Holmes; R E Wolf
Journal:  Clin Rheumatol       Date:  1995-03       Impact factor: 2.980

8.  CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.

Authors:  Yasutaka Kakinoki; Hiroya Kubota; Yasushi Yamamoto
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

9.  O antigen allows B. parapertussis to evade B. pertussis vaccine-induced immunity by blocking binding and functions of cross-reactive antibodies.

Authors:  Xuqing Zhang; Maria Eugenia Rodríguez; Eric T Harvill
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

10.  The effect of recombinant granulocyte colony-stimulating factor on oral and periodontal manifestations in a patient with cyclic neutropenia: a case report.

Authors:  Sergio Matarasso; Vincenzo Daniele; Vincenzo Iorio Siciliano; Michele D Mignogna; Gianmaria Andreuccetti; Carlo Cafiero
Journal:  Int J Dent       Date:  2010-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.